Conversion of paid subscribed units and first day of trading with warrants of series TO3
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. The rights issue of shares and warrants of series TO3 in Biosergen AB (“Biosergen” or the “Company”), which was announced on January 30, 2024 and approved by the extraordinary general meeting on March 1, 2024 (the “Rights Issue”), has been registered with the